Antibiotic Resistance of Acinetobacter baumannii

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Mechanism and Evolution of Antibiotic Resistance".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 5774

Special Issue Editors

Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China
Interests: microbial genomics; bioinformatics; antimicrobial resistance mechanisms; genomic epidemiology; Acinetobacter baumannii

E-Mail Website
Guest Editor
Department School of Medicine, Zhejiang University Medical Center, Hangzhou, China
Interests: microfluidics; single cell sequencing; material chemistry

E-Mail Website
Guest Editor
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Interests: mechanisms of drug resistance, virulence and molecular epidemiology in Gram-negative bacteria; antimicrobial treatment of drug-resistant bacterial infections

Special Issue Information

Dear Colleagues,

Acinetobacter baumannii has become a significant nosocomial pathogen with increasing resistance to antibiotics. The World Health Organization considers the development of new therapeutics against A. baumannii a critical priority to public health, and the US Centers for Disease Control and Prevention considers A. baumannii an urgent threat to public health. The major goal of this Special Issue is to expand the knowledge about the development of resistance, the epidemiology, and the transmission dynamics of antimicrobial resistance to the last-resort antibiotics (e.g., carbapenems, tigecycline, colistin, and cefiderocol) against multidrug-resistant A. baumannii infections. Genomic epidemiological and spatial-temporal analysis of the international multidrug-resistant high-risk clones are more than welcome. Studies that attempt to identify new resistance mechanisms, explore newly discovered antimicrobial agents, and to introduce novel methods to address them will be very much appreciated. This Special Issue encourages the collection of both original research articles and reviews that make substantial advances within this field. We seek a multidisciplinary approach, with authors acting as researchers in universities, academic institutes, centers for disease control and hospitals, as well as those who work in fields including clinical microbiology, environmental and veterinary sciences to contribute.

Prof. Dr. Zhi Ruan
Dr. Yongcheng Wang
Dr. Hua Zhou
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Acinetobacter baumannii
  • whole-genome sequencing
  • genomic epidemiology
  • antibiotic resistance
  • molecular epidemiology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 1336 KiB  
Article
Acinetobacter baumannii under Acidic Conditions Induces Colistin Resistance through PmrAB Activation and Lipid A Modification
by Seo-Yeon Ko, Nayeong Kim, Seong-Yong Park, Seong-Yeop Kim, Minsang Shin and Je-Chul Lee
Antibiotics 2023, 12(5), 813; https://doi.org/10.3390/antibiotics12050813 - 26 Apr 2023
Cited by 5 | Viewed by 2082
Abstract
Colistin is a last-resort antimicrobial agent for treating carbapenem-resistant Acinetobacter baumannii infections. The activation of PmrAB by several environmental signals induces colistin resistance in Gram-negative bacteria. This study investigated the molecular mechanisms of colistin resistance in A. baumannii under acidic conditions using wild-type [...] Read more.
Colistin is a last-resort antimicrobial agent for treating carbapenem-resistant Acinetobacter baumannii infections. The activation of PmrAB by several environmental signals induces colistin resistance in Gram-negative bacteria. This study investigated the molecular mechanisms of colistin resistance in A. baumannii under acidic conditions using wild-type (WT) A. baumannii 17978, ΔpmrA and ΔpmrB mutants, and pmrA-complemented strains. The pmrA or pmrB deletion did not affect the growth of A. baumannii under acidic or aerobic conditions. A. baumannii under acidic (pH 5.5) and high-iron (1 mM) conditions showed 32- and 8-fold increases in the minimum inhibitory concentrations (MICs) of colistin, respectively. The ΔpmrA and ΔpmrB mutants at pH 5.5 showed a significant decrease in colistin MICs compared to the WT strain at pH 5.5. No difference in colistin MICs was observed between WT and mutant strains under high-iron conditions. The pmrCAB expression significantly increased in the WT strain at pH 5.5 compared to the WT strain at pH 7.0. The pmrC expression significantly decreased in two mutant strains at pH 5.5 compared to the WT strain at pH 5.5. The PmrA protein was expressed in the ΔpmrA strain carrying ppmrA_FLAG plasmids at pH 5.5 but not at pH 7.0. Lipid A modification by the addition of phosphoethanolamine was observed in the WT strain at pH 5.5. In conclusion, this study demonstrated that A. baumannii under acidic conditions induces colistin resistance via the activation of pmrCAB operon and subsequent lipid A modification. Full article
(This article belongs to the Special Issue Antibiotic Resistance of Acinetobacter baumannii)
Show Figures

Figure 1

11 pages, 308 KiB  
Article
In Vitro Activity of Sulbactam–Durlobactam against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Multicentre Report from Italy
by Bernardetta Segatore, Alessandra Piccirilli, Sabrina Cherubini, Luigi Principe, Giovanni Alloggia, Maria Lina Mezzatesta, Mario Salmeri, Stefano Di Bella, Roberta Migliavacca, Aurora Piazza, Elisa Meroni, Paolo Fazii, Daniela Visaggio, Paolo Visca, Venere Cortazzo, Giulia De Angelis, Arianna Pompilio and Mariagrazia Perilli
Antibiotics 2022, 11(8), 1136; https://doi.org/10.3390/antibiotics11081136 - 22 Aug 2022
Cited by 8 | Viewed by 2420
Abstract
In the present study, the in vitro activity of the sulbactam–durlobactam (SUL–DUR) combination was evaluated against 141 carbapenem-resistant A. baumannii (CRAb) clinical strains collected from six Italian laboratories. Over half (54.6%) of these isolates were resistant to colistin. The SUL–DUR combination [...] Read more.
In the present study, the in vitro activity of the sulbactam–durlobactam (SUL–DUR) combination was evaluated against 141 carbapenem-resistant A. baumannii (CRAb) clinical strains collected from six Italian laboratories. Over half (54.6%) of these isolates were resistant to colistin. The SUL–DUR combination was active against these CRAb isolates with MIC50 and MIC90 values of 0.5 mg/L and 4 mg/L, respectively. Only eleven isolates were resistant to SUL–DUR with MIC values ranging from 8 to 128 mg/L. The SUL–DUR resistant A. baumannii exhibited several antimicrobial resistance genes (ARGs) such as blaOXA-20, blaOXA-58, blaOXA-66, blaADC-25, aac(6′)-Ib3 and aac(6′)-Ib-cr and mutations in gyrA (S81L) and parC (V104I, D105E). However, in these isolates, mutations Q488K and Y528H were found in PBP3. Different determinants were also identified in these CRAb isolates, including adeABC, adeFGH, adeIJK, abeS, abaQ and abaR, which encode multidrug efflux pumps associated with resistance to multiple antibacterial agents. This is the first report on the antimicrobial activity of SUL–DUR against carbapenem-resistant A. baumannii isolates selected from multiple regions in Italy. Full article
(This article belongs to the Special Issue Antibiotic Resistance of Acinetobacter baumannii)
Back to TopTop